Pharmaceutical Marketing's Contributions to Quality of Life

REFERENCES

• Merck and Company. About Merck [resource on World Wide Web]. URL: http://www.merck.com/about/. Available from Internet. Accessed 2001 Mar 7.
   Google Scholar
• Kotler P. Principles of marketing. 3rd ed. Englewood Cliffs, NJ: Prentice-Hall; 1986.
   Google Scholar
• Wilkie WL, Moore ES. Marketing's contributions to society. J Marketing. 1999; 63(Special Issue):198-218. (reprinted in this issue of JPMM on pp. 11–56)
   Google Scholar
• Sirgy MJ, Meadow HL, Samli AC. Past, present, and future: An overview of quality of life research in marketing. In: New dimensions in marketing/quality of life research. Sirgy MJ, Samli AC, eds. Westport, CT: Quorum Books; 1995:335–64.
   Google Scholar
• Patrick DL, Chiang YP. Measurement of health outcomes in treatment effec-tiveness evaluations: Conceptual and methodological challenges. Med Care. 2000; 38 (9 Suppl):II144125.
   Google Scholar
• Glossary: Health outcomes methodology. Med Care. 2000; 38(9 Suppl): 1174113.
   Google Scholar
• Morris MH, Sexton DL, Lewis PS. Small business, entrepreneurship, and qual-ity of life: A growth perspective. In: New dimensions in marketing/quality of life re-search. Sirgy MJ, Samli AC, eds. Westport, CT: Quorum Books; 1995:71–94.
   Google Scholar
• Sirgy MJ, Lee DJ. Setting socially responsible marketing objectives: A quality of life approach. Eur J Marketing. 1996; 30(5):20–34.
   Google Scholar
• Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the valid-ity of quality of life claims for labeling and promotion. Value in Health. 1999; 2:113–27.
   Google Scholar
• Ware JE. The status of health assessment 1994. Aim Rev Public Health. 1995; 16:327–54.
   PubMedGoogle Scholar
• Sirgy MJ, Samli AC, eds. New dimensions in marketing/quality of life research. Westport, CT: Quorum Books; 1995.
   Google Scholar
• Kotler P. Marketing management: Analysis, planning, implementation, and control. 7th ed. Englewood Cliffs, NJ: Prentice-Hall; 1991.
   Google Scholar
• Shaw EH. Book review: New dimensions in marketing/quality of life research. J Macromarketing. 1997; 17:132–5.
   Google Scholar
• Schoell WF, Guiltinan JP. Marketing: Contemporary concepts and practices. 4th ed. Boston: Allyn and Bacon; 1990.
   Google Scholar
• Morris LA, Beckett TK, Lechter KJ. A marketing perspective: Theoretical un-derpinnings. In: Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Spilker B, ed. Philadelphia: Lippincott-Raven Publishers; 1996:541–8.
   Google Scholar
• Revicki DA, Ehreth JL. Health-related quality of life assessment and planning for the pharmaceutical industry. Clin Ther. 1997; 19:1101–15.
   PubMed Web of Science ®Google Scholar
• Burke LB. U.S. regulation of pharmaceutical outcomes research. Value in Health. 2001; 4:5–7.
   PubMedGoogle Scholar
• Spilker B, Garbus SB. An industry perspective. In: Quality of life and pharma-coeconomics in clinical trials. 2nd ed. Spilker B, ed. Philadelphia: Lippincott-Raven Publishers; 1996:535–40.
   Google Scholar
• Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314:1657–64.
   PubMed Web of Science ®Google Scholar
• Jack W. Pharmaceutical differentiation through quality of life measurement: A case study. J Pharm Market Manage. 1991;6(1):65–85.
   Google Scholar
• Brock D. Quality of life measures in health care and medical ethics. In: Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Spilker B, ed. Philadelphia: Lippincott-Raven Publishers; 1996:497–510.
   Google Scholar
• Spilker B. Multinational pharmaceutical companies: Principles and practices. 2nd ed. New York: Raven Press; 1994.
   Google Scholar
• McHorney CA. Concepts and measurement of health status and health-related quality of life. In: Handbook of social studies in health and medicine. Albrecht GL, Fitzpatrick R, Scrimshaw SC, eds. Thousand Oaks, CA: SAGE Publications; 2000: 339–58.
   Google Scholar
• Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996.
   Google Scholar
• Staquet MJ, Hays RD, Fayers PM, eds. Quality of life assessment in clinical tri-als: Methods and practice. New York: Oxford University Press; 1998.
   Google Scholar
• Lohr KN. Health outcomes methodology symposium: Summary and recom-mendations. Med Care. 2000; 38(9 Suppl):11194–11208.
   Google Scholar
• Bungay KM, Ware JE. Current concepts: Measuring and monitoring health-re-lated quality of life. Kalamazoo, MI: The Upjohn Company; 1993.
   Google Scholar
• Merck and Company. Merck corporate philanthropy report [resource on World Wide Web]. URL: http://www.merck.com/overview/philanthropy/. Available from Internet. Accessed 2001 Mar 7.
   Google Scholar
• Eli Lilly and Company. Eli Lilly and Company Foundation Web Page [resource on World Wide Web]. URL: http://www.lilly.com/about/community/foundation/ index.html. Available from Internet. Accessed 2001 Mar 7.
   Google Scholar
• Manasse HR. Medication use in an imperfect world: Drug misadventuring as an issue of public policy, Part 1. Am J Hosp Pharm. 1989;46:929–44.
   PubMedGoogle Scholar
• Manas se HR. Medication use in an imperfect world: Drug misadventuring as an issue of public policy, Part 2. Am J Hosp Pharm. 1989; 46:1141–52.
   PubMedGoogle Scholar
• Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47:533–43.
   PubMedGoogle Scholar
• Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-ill-ness model. Arch Intern Med. 1995; 155:1949–56.
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hos-pitalized patients: A meta-analysis of prospective studies. JAMA. 1998; 279:1200–5.
   Google Scholar
• Murawski MM, Bentley JP. Pharmaceutical therapy-related quality of life: Conceptual development. J Soc Admin Pharm. 2001; 18:2–14.
   Google Scholar
• Holton MF. Direct-to-consumer marketing of prescription drugs: Creating con-sumer demand. JAMA. 1999; 281:382–4.
   PubMedGoogle Scholar
• Angell M. The pharmaceutical industry—to whom is it accountable? N Engl J Med. 2000; 342:1902–4.
   Google Scholar